Checkpoint Therapeutics Inc CKPT

Morningstar Rating
$2.22 +0.04 (1.83%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CKPT is trading at a 188% premium.
Price
$2.25
Fair Value
$7.94
Uncertainty
Extreme
1-Star Price
$696.28
5-Star Price
$9.00
Economic Moat
Fvsnx
Capital Allocation

News

Trading Information

Previous Close Price
$2.18
Day Range
$2.182.23
52-Week Range
$1.363.62
Bid/Ask
$2.19 / $2.23
Market Cap
$99.94 Mil
Volume/Avg
247,458 / 383,903

Key Statistics

Price/Earnings (Normalized)
Price/Sales
832.08
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
23

Comparables

Valuation

Metric
CKPT
PRLD
CGON
Price/Earnings (Normalized)
Price/Book Value
0.604.42
Price/Sales
832.08244.06
Price/Cash Flow
Price/Earnings
CKPT
PRLD
CGON

Financial Strength

Metric
CKPT
PRLD
CGON
Quick Ratio
0.237.7146.66
Current Ratio
0.267.8347.57
Interest Coverage
Quick Ratio
CKPT
PRLD
CGON

Profitability

Metric
CKPT
PRLD
CGON
Return on Assets (Normalized)
−479.97%−40.98%−15.24%
Return on Equity (Normalized)
−46.70%−26.61%
Return on Invested Capital (Normalized)
−44.57%−25.60%
Return on Assets
CKPT
PRLD
CGON

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
CvghjjjhyZzq$512.4 Bil
Vertex Pharmaceuticals Inc
VRTX
CrqfksvfCgvmwz$117.5 Bil
Regeneron Pharmaceuticals Inc
REGN
LqsmfsjSldptv$111.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
WnfpgbsmcJcwvnm$34.4 Bil
argenx SE ADR
ARGX
VrwmtjwsJvks$31.7 Bil
BioNTech SE ADR
BNTX
PjlmncsqCjww$29.2 Bil
Moderna Inc
MRNA
HyjqyvnxZpc$23.1 Bil
United Therapeutics Corp
UTHR
JyfjftzQdq$15.8 Bil
Biomarin Pharmaceutical Inc
BMRN
CdcjvbpQgsqdd$13.2 Bil
Incyte Corp
INCY
YckvshhTyhtzx$13.0 Bil

Sponsor Center